Loading stock…

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Alnylam Pharmaceuticals, Inc.

ALNYMarket cap $30BPrice $224.4

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops RNA interference drugs that silence disease-causing genes before they make harmful proteins. Their hemophilia treatment eliminates the need for regular injections, transforming patient care through genetic precision.

In Bastion Portfolios?

52W Return-53%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+53%10

Revenue Forecast

Rev CAGR (1y)+47%10

Rev CAGR (3y)+30%10

Rev CAGR (5y)+23%10

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+42%9

EPS Growth Y+3+27%8

Quality

Margins

EBIT Margin21%8

Net Income Margin16%7

Free Cash Flow Margin17%7

Debt

Net Debt/EBITDA-0.310

Efficiency

ROE97%10

ROA15%9

Earnings Stability22

GEAR+STRONG82

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)194

P/E Ratio (Forward 3y)145

P/BV22.21

EV Multiples

EV/EBITDA Fwd252

EV/EBIT Fwd273

Yield

Free Cash Flow Yield2.7%4

Dividend Yieldna–

Momentum

Short term

1 month return-14%2

3 month return-31%1

YTD return-44%1

Mid term

Price vs 52wHigh45%1

1 year return-50%1

Long term

3 year return+27%4

5 year return+10%4

Risk Shield

Price Risk

Beta0.94

Volatility51%3

Free Cash Flow

Free Cash Flow Margin17%7

Free Cash Flow Yield2.7%4

Quality

ROCE27%9

Earnings Stability22

Net Debt/EBITDA-0.310

02Growth

Is it actually growing, and how fast?

ALNYAlnylam Pharmaceuticals

Revenue FY25$2.2B

GROWTH RATING↗

VERY STRONG97 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+53%10

Revenue, next 1Y+47%10

Revenue, next 3Y, CAGR+30%10

Revenue, next 5Y, CAGR+23%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+42%9

EPS growth, FY28E+27%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 97% of companies worldwide.

Revenue grew 53%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 30%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 23%/yr over five years.10/10

Earnings are set to grow in step with sales (EPS about 27%/yr vs revenue 30%/yr).

WATCH

Revenue grew 53%/yr over the last 3 years; forecasts see it cooling to 30%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK5 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-14%2

3-month return-31%1

YTD return-44%1

MID & LONG-TERM▾SCORE

% of 52-week high45%1

1-year return-50%1

3-year return+27%4

5-year return+10%4

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+27% over three years and +10% over five), roughly average for the market.

WEAKNESSES

It's down 50% over the past year, now 55% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-14%), over three months (-31%) and so far this year (-44%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Alnylam Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ALNYAlnylam Pharmaceuticals

Revenue FY25$2.2B

GROWTH RATING↗

VERY STRONG97 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+53%10

Revenue, next 1Y+47%10

Revenue, next 3Y, CAGR+30%10

Revenue, next 5Y, CAGR+23%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+42%9

EPS growth, FY28E+27%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 97% of companies worldwide.

Revenue grew 53%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 30%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 23%/yr over five years.10/10

Earnings are set to grow in step with sales (EPS about 27%/yr vs revenue 30%/yr).

WATCH

Revenue grew 53%/yr over the last 3 years; forecasts see it cooling to 30%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK5 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-14%2

3-month return-31%1

YTD return-44%1

MID & LONG-TERM▾SCORE

% of 52-week high45%1

1-year return-50%1

3-year return+27%4

5-year return+10%4

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+27% over three years and +10% over five), roughly average for the market.

WEAKNESSES

It's down 50% over the past year, now 55% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-14%), over three months (-31%) and so far this year (-44%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Alnylam Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community